NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 143 filers reported holding NEKTAR THERAPEUTICS in Q3 2013. The put-call ratio across all filers is 0.44 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $30,000 | -41.2% | 1,766 | -20.2% | 0.00% | -33.3% |
| Q2 2020 | $51,000 | +24.4% | 2,213 | -2.7% | 0.01% | 0.0% |
| Q1 2020 | $41,000 | -19.6% | 2,275 | -3.6% | 0.01% | 0.0% |
| Q4 2019 | $51,000 | +10.9% | 2,360 | -7.5% | 0.01% | +20.0% |
| Q3 2019 | $46,000 | -65.2% | 2,551 | -31.6% | 0.01% | -64.3% |
| Q2 2019 | $132,000 | -5.7% | 3,728 | -10.2% | 0.01% | -57.6% |
| Q1 2019 | $140,000 | -5.4% | 4,150 | -7.7% | 0.03% | -8.3% |
| Q4 2018 | $148,000 | -58.8% | 4,497 | -23.7% | 0.04% | -49.3% |
| Q3 2018 | $359,000 | +56.8% | 5,891 | +25.7% | 0.07% | +54.3% |
| Q2 2018 | $229,000 | -52.3% | 4,685 | +3.6% | 0.05% | -54.0% |
| Q1 2018 | $480,000 | +61.1% | 4,524 | -9.2% | 0.10% | +72.4% |
| Q4 2017 | $298,000 | +223.9% | 4,984 | -25.4% | 0.06% | +427.3% |
| Q1 2016 | $92,000 | -31.9% | 6,683 | -16.6% | 0.01% | -21.4% |
| Q4 2015 | $135,000 | 0.0% | 8,013 | -31.2% | 0.01% | +16.7% |
| Q2 2013 | $135,000 | – | 11,650 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CM Management, LLC | 750,000 | $930,000 | 0.85% |
| Deep Track Capital, LP | 17,875,498 | $22,165,618 | 0.66% |
| Acuitas Investments, LLC | 879,904 | $1,091,081 | 0.58% |
| TCG Crossover Management, LLC | 4,000,000 | $4,960,000 | 0.52% |
| Almitas Capital LLC | 920,225 | $1,141,079 | 0.47% |
| Monaco Asset Management SAM | 2,166,432 | $2,686,376 | 0.43% |
| Shay Capital LLC | 1,840,377 | $2,282,067 | 0.32% |
| Nantahala Capital Management | 4,110,000 | $5,096,400 | 0.30% |
| Ikarian Capital, LLC | 1,312,405 | $1,627,382 | 0.28% |
| SAMLYN CAPITAL, LLC | 9,457,887 | $11,727,781 | 0.20% |